Literature DB >> 3308707

Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin.

D T Golenbock1, J A Will, C R Raetz, R A Proctor.   

Abstract

Lipid X (2,3-diacylglucosamine-1-phosphate) is a novel monosaccharide precursor of lipid A that has some of the physiologic activities of endotoxin but little toxicity. To determine whether lipid X would interfere with the toxic effects of endotoxin, we pretreated sheep with either 100 or 200 micrograms of lipid X per kg of body weight and then challenged them with a potentially fatal dose of Escherichia coli endotoxin (20 micrograms/kg). Twenty-one sheep underwent pulmonary artery catheterization and were monitored for changes in pulmonary artery pressure, temperature, pH, partial O2 pressure, partial CO2 pressure, blood pressure, and cell counts over 7 h. Overall mortality for control animals was 37% versus 5.3% for pretreated animals. None of the 13 animals pretreated with 100 micrograms of lipid X per kg died. These differences in survival were significant (P less than 0.05). Animals pretreated with 100 micrograms of lipid X per kg had significantly lower pulmonary artery pressure during both phases 1 and 2 of endotoxin-induced pulmonary artery hypertension. A higher dose of lipid X, 200 micrograms/kg, produced pulmonary hypertension. Perhaps because lipid X is a subunit of lipid A, lipid X shows a partial pyrogenic effect while also decreasing the pyrogenic activity of complete lipopolysaccharide (LPS). Lipid X did not prevent endotoxin-induced neutropenia or moderate hypotension in response to LPS. Lipid X is a potential prototype compound for a new type of chemotherapy directed at blocking the harmful effects of LPS during bacterial septicemia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3308707      PMCID: PMC260732          DOI: 10.1128/iai.55.10.2471-2476.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

Review 1.  Bacterial toxins.

Authors:  L J Berry
Journal:  CRC Crit Rev Toxicol       Date:  1977-11

2.  Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis.

Authors:  J L Shenep; R P Barton; K A Mogan
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

Review 3.  Endotoxic immunity.

Authors:  A I Braude
Journal:  Adv Intern Med       Date:  1980

4.  Lung injury and lung lysosomal enzyme release during endotoxemia.

Authors:  R H Demling; R Proctor; J Grossman; N Duy; J Starling
Journal:  J Surg Res       Date:  1981-02       Impact factor: 2.192

5.  Pressor effect of naloxone in septic shock.

Authors:  W P Peters; M W Johnson; P A Friedman; W E Mitch
Journal:  Lancet       Date:  1981-03-07       Impact factor: 79.321

6.  Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations.

Authors:  L S Young; W J Martin; R D Meyer; R J Weinstein; E T Anderson
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

7.  Two interacting mutations causing temperature-sensitive phosphatidylglycerol synthesis in Escherichia coli membranes.

Authors:  M Nishijima; C E Bulawa; C R Raetz
Journal:  J Bacteriol       Date:  1981-01       Impact factor: 3.490

8.  Elevated thromboxane levels in the rat during endotoxic shock: protective effects of imidazole, 13-azaprostanoic acid, or essential fatty acid deficiency.

Authors:  J A Cook; W C Wise; P V Halushka
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

9.  Effectiveness of steroid/antibiotic treatment in primates administered LD100 Escherichia coli.

Authors:  L B Hinshaw; B K Beller-Todd; L T Archer; B Benjamin; D J Flournoy; R Passey; M F Wilson
Journal:  Ann Surg       Date:  1981-07       Impact factor: 12.969

10.  Cross-reactive immunoprotective antibodies to Escherichia coli O111 rough mutant J5.

Authors:  R Sakulramrung; G J Domingue
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

View more
  15 in total

1.  E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.

Authors:  T Kawata; J R Bristol; D P Rossignol; J R Rose; S Kobayashi; H Yokohama; A Ishibashi; W J Christ; K Katayama; I Yamatsu; Y Kishi
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

2.  Immunostimulatory, but not antiendotoxin, activity of lipid X is due to small amounts of contaminating N,O-acylated disaccharide-1-phosphate: in vitro and in vivo reevaluation of the biological activity of synthetic lipid X.

Authors:  C Lam; J Hildebrandt; E Schütze; B Rosenwirth; R A Proctor; E Liehl; P Stütz
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

3.  Bacterial lipopolysaccharide-stimulated GTPase activity in RAW 264.7 macrophage membranes.

Authors:  T Tanke; J W van de Loo; H Rhim; P S Leventhal; R A Proctor; P J Bertics
Journal:  Biochem J       Date:  1991-07-15       Impact factor: 3.857

4.  Optimal induction of tumor necrosis factor production in human monocytes requires complete S-form lipopolysaccharide.

Authors:  D N Männel; W Falk
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

5.  Elimination and tissue distribution of the monosaccharide lipid A precursor, lipid X, in mice and sheep.

Authors:  D T Golenbock; S Ebert; J A Will; R A Proctor
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

Review 6.  Immunotherapy in the management of sepsis.

Authors:  E A Fagan; M Singer
Journal:  Postgrad Med J       Date:  1995-02       Impact factor: 2.401

7.  Biological activity of synthetic phosphonooxyethyl analogs of lipid A and lipid A partial structures.

Authors:  A J Ulmer; H Heine; W Feist; S Kusumoto; T Kusama; H Brade; U Schade; E T Rietschel; H D Flad
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

8.  Resilience to bacterial infection: difference between species could be due to proteins in serum.

Authors:  H Shaw Warren; Catherine Fitting; Eva Hoff; Minou Adib-Conquy; Laura Beasley-Topliffe; Brenda Tesini; Xueya Liang; Catherine Valentine; Judith Hellman; Douglas Hayden; Jean-Marc Cavaillon
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

9.  Inhibition of endotoxin-induced interleukin-6 production by synthetic lipid A partial structures in human peripheral blood mononuclear cells.

Authors:  M H Wang; H D Flad; W Feist; H Brade; S Kusumoto; E T Rietschel; A J Ulmer
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

10.  Lipid X protects mice against fatal Escherichia coli infection.

Authors:  D T Golenbock; J E Leggett; P Rasmussen; W A Craig; C R Raetz; R A Proctor
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.